[Skip to Content]
[Skip to Content Landing]
July 26, 1952


Author Affiliations


From the Hektoen Institute for Medical Research of the Cook County Hospital, the Department of Medicine, Stritch School of Medicine, Loyola University (Dr. Pascale), and the Department of Physiology, University of Illinois College of Medicine (Dr. Hoffman).

JAMA. 1952;149(13):1188-1194. doi:10.1001/jama.1952.02930300014004

Probenecid (benemid®) was first introduced into clinical medicine by Boger1 as an adjunct to penicillin and paraaminosalicylic acid therapy. Probenecid has been found to be a powerful agent that reversibly inhibits renal tubular transfer, suppressing tubular secretion of penicillin, paraaminosalicylic acid, paraaminohippuric acid, and phenolsulfonphthalein.2 In this respect it is similar to carinamide; but while the latter is required in doses of 18 to 24 gm. per day for its tubular effect, probenecid accomplishes the same results in doses of 2 gm. daily. That probenecid, like carinamide, is also capable of blocking tubular reabsorption of glomerular constituents was demonstrated by Schneider and Corcoran,3 who were able to increase the excretion of phosphate by administration of the drug. Gutman, acting on the report by Wolfson and associates4 that carinamide was a uricosuric agent, demonstrated that probenecid had a similar effect, presumably by blocking the partial reabsorption of

First Page Preview View Large
First page PDF preview
First page PDF preview